MedTrace Logo

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04501666 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 286

Last updated 2024-07-10

Study results available
· View outcomes & findings →

Summary

The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (\>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.

Conditions

  • Prurigo Nodularis

Interventions

DRUG

Nemolizumab 30 mg

Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.

DRUG

Placebo

Participants received matching placebo as SC injection.

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-11
Primary Completion
2022-11-11
Completion
2023-02-21
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Canada
  • Denmark
  • Germany
  • Hungary
  • Italy
  • Poland
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04501666 on ClinicalTrials.gov